Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.
A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to...